Daniel A. Peisert
2019 - DepoMed
In 2019, Daniel A. Peisert earned a total compensation of $1.6M as Senior Vice President and Chief Financial Officer at DepoMed, a 68% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $213,241 |
|---|---|
| Salary | $406,667 |
| Stock Awards | $925,291 |
| Other | $63,890 |
| Total | $1,609,089 |
Peisert received $925.3K in stock awards, accounting for 58% of the total pay in 2019.
Peisert also received $213.2K in non-equity incentive plan, $406.7K in salary and $63.9K in other compensation.
Rankings
In 2019, Daniel A. Peisert's compensation ranked 6,990th out of 13,971 executives tracked by ExecPay. In other words, Peisert earned more than 50.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,990 out of 13,971 | 50th |
Division Manufacturing | 2,675 out of 5,701 | 53rd |
Major group Chemicals And Allied Products | 981 out of 2,200 | 55th |
Industry group Drugs | 830 out of 1,886 | 56th |
Industry Pharmaceutical Preparations | 609 out of 1,398 | 56th |
Source: SEC filing on April 20, 2020.
Peisert's colleagues
We found two more compensation records of executives who worked with Daniel A. Peisert at DepoMed in 2019.
News
Assertio Holdings CEO Arthur Higgins' 2020 pay falls 48% to $2.5M
April 12, 2021
Egalet CEO Arthur Higgins' 2019 pay rises 2% to $4.9M
April 20, 2020
DepoMed CEO Arthur Higgins' 2019 pay rises 2% to $4.9M
April 20, 2020
Egalet CEO Arthur Higgins' 2018 pay stays at $4.8M
November 6, 2019
DepoMed CEO Arthur Higgins' 2018 pay stays at $4.8M
April 8, 2019